検索
Jazz Pharmaceuticals PLC
JAZZウォッチリストに追加
252.860USD
-5.520-2.14%
終値 07-31 16:00（ET）15分遅れの株価
15.53B時価総額
613.23直近12ヶ月PER
詳細情報 Jazz Pharmaceuticals PLC 企業名
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Jazz Pharmaceuticals PLCの企業情報
企業コードJAZZ
会社名Jazz Pharmaceuticals PLC
上場日Jan 18, 2012
最高経営責任者「CEO」Gala (Renee D)
従業員数2800
証券種類Ordinary Share
決算期末Jan 18
本社所在地Fifth Floor, Waterloo Exchange
都市DUBLIN
証券取引所NASDAQ OMX - NASDAQ BASIC
国Ireland
郵便番号- -
電話番号35316347800
ウェブサイトhttps://www.jazzpharma.com/
企業コードJAZZ
上場日Jan 18, 2012
最高経営責任者「CEO」Gala (Renee D)
Jazz Pharmaceuticals PLCの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.54%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
327.80K
-1.83%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.05K
-10.25%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
45.42K
-8.29%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
24.89K
-13.43%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
20.75K
-18.69%
Ms. Samantha Pearce
Ms. Samantha Pearce
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
20.26K
-12.47%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Director
Independent Director
17.65K
+30.00%
Ms. Anne O'Riordan
Ms. Anne O'Riordan
Independent Director
Independent Director
16.50K
+21.25%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
10.84K
+32.36%
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.54%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
327.80K
-1.83%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.05K
-10.25%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
45.42K
-8.29%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
24.89K
-13.43%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
20.75K
-18.69%
よくある質問
Jazz Pharmaceuticals PLCの上位5名の株主は誰ですか？
Jazz Pharmaceuticals PLCの上位5名の株主は以下のとおりです。Mr. Seamus C. Mulligan
Jazz Pharmaceuticals PLC（JAZZ）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Jazz Pharmaceuticals PLCの株式を保有している機関は1229社あり、保有株式の総市場価値は約70.31Mで、全体の112.06%を占めています。2025Q4と比較して、機関の持ち株は-754072.00増加しています。
Jazz Pharmaceuticals PLCの最大の収益源は何ですか？
2026Q1において、Xywav部門がJazz Pharmaceuticals PLCにとって最大の収益を生み出しており、その金額は1.66Bで、全収益の38.83%を占めています。